RxDoctor Payments Data

Margaret Marashian, NP

Nurse Practitioner · Wheeling, WVNPI 1649626268

Payments from drug & device makers

$1,695in general payments, 2019–2025

Across 45 payments — averaging $37.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$555
  • Boston Scientific$243
  • Actelion Pharmaceuticals US, Inc.$210
  • Edwards Lifesciences$136
  • Abiomed$136
  • AstraZeneca$134
  • plus $280 from 8 others

What the payments were for

  • Food & beverage$1,66898%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,695 in reported general payments places this provider in the 85th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$27,642
Medicare patients
298
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$226,190
XareltoRivaroxaban58$57,455
BrilintaTicagrelor64$48,729
EntrestoSacubitril/Valsartan36$45,503
JardianceEmpagliflozin19$22,741
FarxigaDapagliflozin Propanediol21$22,415
Repatha SureclickEvolocumab20$17,753
Ranolazine ErRanolazine41$5,524
Metoprolol Succinate356$5,476
Atorvastatin Calcium249$2,807
Rosuvastatin Calcium148$1,884
ClopidogrelClopidogrel Bisulfate172$1,807
Valsartan44$1,459
Ezetimibe48$1,289
Losartan Potassium140$1,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$226,190211 claims
AstraZenecaBrilinta, Farxiga$134$71,14485 claims
Johnson & JohnsonXarelto$15$57,45558 claims
NovartisEntresto$16$45,50336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →